Publications by authors named "J Garcia-Saenz"
Standard treatments in hormone receptor-positive (HR+)/HER2-metastatic breast cancer (mBC) typically involve endocrine therapy (ET) combined with CDK4/6 inhibitors, yet resistance to ET remains a persistent challenge in advanced cases. A deeper knowledge of the use of liquid biopsy is crucial for the implementation of precision medicine in mBC with real-time treatment guidance. Our study assesses the prognostic value of and mutations in DNA derived from extracellular vesicles (EV-DNA) in longitudinal plasma from 59 HR+/HER2-mBC patients previously exposed to aromatase inhibitors, with a comparative analysis against circulating tumor DNA (ctDNA).
View Article and Find Full Text PDFArticle Synopsis
- Imlunestrant is a next-generation oral selective estrogen receptor degrader being tested in the EMBER trial for patients with ER+ advanced breast cancer and endometrioid endometrial cancer (EEC).
- The trial involves a dose-escalation design to determine optimal doses and measure safety, pharmacokinetics, and anticancer effects, focusing specifically on patients who have already undergone certain previous treatments.
- Results showed manageable side effects and some evidence of antitumor activity, with better outcomes observed when imlunestrant was combined with abemaciclib compared to imlunestrant alone.
Background: Identification of biomarkers to optimize treatment strategies for early-stage triple-negative breast cancer (TNBC) is crucial. This study presents the development and validation of TNBC-DX, a novel test aimed at predicting both short- and long-term outcomes in early-stage TNBC. The objective of this study was to evaluate the association between TNBC-DX and efficacy outcomes [pathologic complete response (pCR), distant disease-free survival (DDFS) or event-free survival (EFS), and overall survival (OS)] in the validation cohorts.
View Article and Find Full Text PDFArticle Synopsis
- This study looked at how a medicine called nintedanib might help with breast cancer by making the environment around the tumor less stiff.
- Researchers tested this by comparing two groups of patients: one got regular treatment while the other received nintedanib with their treatment.
- They found that although overall survival rates were similar, patients with high stiffness scores (MeCo) had a higher risk of cancer returning, but taking nintedanib lowered that risk.
Background: Leptomeningeal disease (LMD) is associated with poor survival and diminished quality of life. Trastuzumab deruxtecan (T-DXd) has shown remarkable intracranial and extracranial activity in human epidermal growth factor receptor 2 (HER2)-positive and HER2-low advanced breast cancer (ABC). The DEBBRAH trial was designed to evaluate its efficacy and safety in patients with HER2-positive and HER2-low ABC with a history of brain metastases (BMs) and/or LMD.
View Article and Find Full Text PDF